Results 21 to 30 of about 6,511 (194)
Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities. [PDF]
FASEB JInterplay between VEGF‐A‐driven angiogenesis and DRD2‐mediated inhibition. Tumor‐derived VEGF‐A activates VEGFR2 on endothelial cells, triggering proangiogenic signaling pathways that promote abnormal vessel growth and vascular leakage. VEGF‐A also induces DRD2 expression, establishing a feedback mechanism.
Akkanapally V +6 more
europepmc +2 more sources
A Practical Synthesis of Cabergoline [PDF]
The Journal of Organic Chemistry, 2002 Cabergoline is an N-acylurea derived from 9,10-dihydrolysergic acid, which is a potent prolactin inhibitor. It is marketed by Pharmacia as Dostinex for the treatment of hyperprolactinemia and is currently under active development for the treatment of a variety of CNS disorders.
Scott W, Ashford +3 more
openaire +2 more sources
Cabergoline and the risk of valvular lesions in endocrine disease. [PDF]
, 2008 peer reviewedAIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown.
Livadariu, E. +7 more
core +1 more source
Ожирение и метаболизм, 2015 Objective: To evaluate the effectiveness and safety of cabergoline drug Bergolak («Veropharm», Russia) in the treatment of patients with prolactin-secreting tumors.Materials and methods: The study included 14 patients (14 women, mean age 46±12) diagnosed
Galina Afanas'evna Melnichenko +3 more
doaj +1 more source
De Novo Psychiatric Disorders in a Woman With Giant Prolactinoma Treated With Cabergoline
Clinical Medicine Insights: Case Reports, 2023 Dopamine agonists are the first-line treatment of prolactinomas. The risk of developing de novo psychiatric symptoms during dopamine agonist therapy is low.
Chayma Belhadj Slimane +4 more
doaj +1 more source
Saudi Pharmaceutical Journal, 2023 Background: There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on ...
Pouria Rahmanian-Devin +3 more
doaj +1 more source
Cabergoline treatment in acromegaly: pros [PDF]
, 2014 Cabergoline is an ergot-derived dopamine D2 receptor agonist which may be effective for the medical management of acromegaly. Its efficacy in reducing growth hormone and IGF-I levels, as well as its antiproliferative and pro-apoptotic effects on ...
Ramos-Levi, A +3 more
core +1 more source
Middle East Fertility Society Journal, 2011 Background: Prophylactic use of dopamine agonist has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). Objective: To compare cabergoline with cabergoline plus I.V albumin or I.V albumin alone in prevention of ...
Badeea S. Soliman
doaj +1 more source
Giant prolactinoma case with side effects due to cabergoline
, 2020 Dopamine agonists should usually be the first treatment for patients with prolactinomas of all sizes, because these drugs decrease serum prolactin concentrations and decrease the size of most lactotroph adenomas. Cabergoline is preferred first.
Hüseyin Dursun +3 more
core +1 more source
Cabergoline Treatment in Invasive Giant Prolactinoma
, 2014 Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive
Sadeem Alsubaie, Mussa H. Almalki
core +1 more source